Danish drugmaker Novo Nordisk has launched its popular weight loss drug Ozempic in India, with its lowest dose of 0.25 mg priced at Rs 2,200 per week or Rs 8,800 per month, reported Reuters.
Ozempic prices in India unveiled
The once-weekly injectable will be available in 0.25 mg, 0.5 mg and 1 mg doses in India. While 0.5 mg is priced at Rs 10,170 per month, its highest 1 mg dose falls in the price bracket of Rs 11,175 in the country.
Ruling the weight loss space since 2017
Ozempic, a once-a-week injectable brand, was originally approved by US FDA in 2017 to manage Type 2 diabetes, but it was its benefits in weight management that added to his massive popularity. Ozempic since eight years of its launch has transformed lives by helping people with obesity lose significant amount of weight reducing risk of chronic diseases including cardiovascular issues.
How does Ozempic work?
Ozempic, that’s injected weekly, works by bringing down blood sugar levels and decreasing appetite. Recent research also shows promise regarding the drug’s effectiveness in managing addiction, cardiovascular health among others.
A 2021 research published in The New England Journal of Medicine shows that people experienced an average of 15 per cent weight loss on Ozempic over a course of 68 weeks, while those on placebo experienced only a 2 per cent weight loss.
Ozempic side effects
Ozempic experience hasn’t been pleasant for all users as many have experienced unpleasant side effects like nausea, fatigue, muscle loss, changes in vision, severe stomach problems, allergic reactions, and gallbladder problems.
When was it approved in India?
The Central Drugs Standard Control Organisation (CDSCO) gave Novo Nordisk approval for launching the drug in India on September 26, 2025, for use in adults with Type 2 diabetes.
“Semaglutide Injection (Ozempic@) is indicated for the treatment of adults with Insufficiently Controlled Type 2 Diabetes Mellitus as an adjunct to Diet and Exercise,” the approval by CDSCO said on September 26.
India has the second-highest number of people with Type 2 Diabetes after China, as well as rising obesity rates, making it a critical battleground for drugmakers vying for a share of the fast-growing weight-loss treatment market.
Disclaimer: The information in this article is for educational and informational purposes only and is not intended as medical advice. While the author has incorporated expert medical guidance while producing the story and ensured full authentic information is provided to the reader, you should always seek the advice of a qualified healthcare provider regarding a medical condition or treatment. Never disregard professional medical advice or delay in seeking it because of something you have read here.